āĻšā§āĻŽUCBJY âĸ OTCMKTS
add
UCB Unsponsored Belgium ADR
ā§§ā§Ļā§Ļ.ā§¨ā§Ŧ$
ā§§ā§§ āĻā§āĻ˛, ā§Ģ:ā§¨ā§Ļ:ā§Ļā§Ļ PM GMT -ā§Ē · USD · OTCMKTS · āĻĄāĻŋāĻ¸āĻā§āĻ˛ā§āĻŽāĻžāĻ°
āĻāĻžāĻ˛ āĻļā§āĻˇ āĻ¯ā§ āĻĻāĻžāĻŽā§ āĻāĻŋāĻ˛
ā§§ā§Ļā§Ļ.ā§¯ā§Ē$
āĻ¸āĻžāĻ°āĻž āĻĻāĻŋāĻ¨ā§āĻ° āĻā§āĻ°ā§āĻĄāĻŋāĻā§ā§ āĻ¸ā§āĻāĻā§āĻ° āĻĻāĻžāĻŽā§āĻ° āĻāĻ āĻž āĻ¨āĻžāĻŽāĻžāĻ° āĻ°ā§āĻā§āĻ
ā§¯ā§¯.ā§Ģā§$ - ā§§ā§Ļā§Ļ.ā§¯ā§Ļ$
āĻ¸āĻžāĻ°āĻž āĻŦāĻāĻ°ā§āĻ° āĻ°ā§āĻā§āĻ
ā§ā§§.ā§§ā§Ŧ$ - ā§§ā§Ļā§Ŧ.ā§Ŧā§Ļ$
āĻŽāĻžāĻ°ā§āĻā§āĻ āĻā§āĻ¯āĻžāĻĒ
ā§Šā§Š.ā§Žā§ĢāĻļāĻ¤Â āĻā§ EUR
āĻāĻĄāĻŧ āĻāĻ˛āĻŋāĻāĻŽ
ā§Šā§§.ā§Ģā§Ŧ āĻšāĻž
āĻŦāĻžāĻāĻžāĻ° āĻ¸āĻāĻŦāĻžāĻĻ
āĻĢāĻžāĻāĻ¨āĻžāĻ¨ā§āĻ¸āĻŋā§āĻžāĻ˛ āĻĒāĻžāĻ°āĻĢāĻ°ā§āĻŽā§āĻ¯āĻžāĻ¨ā§āĻ¸
āĻā§ā§āĻ° āĻ¸ā§āĻā§āĻāĻŽā§āĻ¨ā§āĻ
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ
| (EUR) | āĻĄāĻŋāĻ¸ā§ ā§¨ā§Ļā§¨ā§Ēinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | ā§§ā§Ŧā§Ž.ā§Ļā§Ģ āĻā§ | ā§¨ā§Ŧ.ā§¨ā§§% |
āĻŦā§āĻ¯āĻŦāĻ¸āĻž āĻāĻžāĻ˛āĻžāĻ¨ā§āĻ° āĻāĻ°āĻ | ā§¯ā§Ŧ.ā§¯ā§Ļ āĻā§ | ā§¨ā§§.ā§Ŧā§Ŧ% |
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | ā§Ēā§¨.ā§Žā§Ģ āĻā§ | ā§¨,ā§Ģā§ā§Ž.ā§§ā§¨% |
āĻ¨ā§āĻ āĻĒā§āĻ°āĻĢāĻŋāĻ āĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ | ā§¨ā§Ģ.ā§Ģā§Ļ | ā§¨,ā§Ļā§¨ā§Ģ.ā§Ļā§Ļ% |
āĻļā§ā§āĻžāĻ° āĻĒā§āĻ°āĻ¤āĻŋ āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | â | â |
EBITDA | ā§Ēā§¨.ā§¨ā§Ģ āĻā§ | ā§Ģā§Ŧ.ā§§ā§¯% |
āĻĒā§āĻ°āĻ¯ā§āĻā§āĻ¯ āĻā§āĻ¯āĻžāĻā§āĻ¸ā§āĻ° āĻšāĻžāĻ° | ā§Ŧ.ā§Ģā§Ē% | â |
āĻŦā§āĻ¯āĻžāĻ˛ā§āĻ¨ā§āĻ¸ āĻļāĻŋāĻ
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
| (EUR) | āĻĄāĻŋāĻ¸ā§ ā§¨ā§Ļā§¨ā§Ēinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻā§āĻ¯āĻžāĻļ āĻ āĻāĻŽ āĻ¸āĻŽā§ā§āĻ° āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ | ā§§ā§Ŧā§.ā§¨ā§Ļ āĻā§ | ā§Žā§§.ā§§ā§Ģ% |
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ | ā§§ā§.ā§Šā§ĢāĻļāĻ¤Â āĻā§ | ā§§ā§§.ā§Ŧā§Ē% |
āĻŽā§āĻ āĻĻāĻžā§ | ā§ā§Šā§§.ā§Žā§Ļ āĻā§ | ā§§ā§§.ā§Ēā§¯% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§§ā§Ļ.ā§Ļā§ŠāĻļāĻ¤Â āĻā§ | â |
āĻāĻāĻāĻ¸ā§āĻā§āĻ¯āĻžāĻ¨ā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāĻ° | ā§§ā§¯.ā§Ļā§Ļ āĻā§ | â |
āĻĒā§āĻ°āĻžāĻāĻ¸ āĻā§ āĻŦā§āĻ āĻ°ā§āĻļāĻŋāĻ | ā§§.ā§¯ā§§ | â |
āĻ¸āĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | ā§Š.ā§ā§Ŧ% | â |
āĻŽā§āĻ˛āĻ§āĻ¨ āĻĨā§āĻā§ āĻā§ | ā§Ģ.ā§Ļā§Ļ% | â |
āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨
| (EUR) | āĻĄāĻŋāĻ¸ā§ ā§¨ā§Ļā§¨ā§Ēinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | ā§Ēā§¨.ā§Žā§Ģ āĻā§ | ā§¨,ā§Ģā§ā§Ž.ā§§ā§¨% |
āĻ
āĻĒāĻžāĻ°ā§āĻļāĻ¨ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āĻ¯āĻžāĻļ | ā§Ēā§Š.ā§¨ā§Ģ āĻā§ | ā§Ŧā§Ž.ā§¯ā§Ģ% |
āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | ā§¨ā§¨.ā§Ŧā§Ļ āĻā§ | ā§Šā§ā§Ļ.ā§Ŧā§Ŧ% |
āĻĢāĻžāĻāĻ¨ā§āĻ¯āĻžāĻ¨ā§āĻ¸āĻŋāĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | -ā§¯.ā§§ā§Ģ āĻā§ | -ā§Ēā§§ā§Ļ.ā§§ā§% |
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ | ā§Ģā§.ā§¨ā§Ģ āĻā§ | ā§§ā§Ŧā§Ž.ā§§ā§Ģ% |
āĻĢā§āĻ°āĻŋ āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§ | ā§Šā§¨.ā§ā§Ģ āĻā§ | ā§Ŧā§Ŧ.ā§Ŧā§§% |
āĻ¸āĻŽā§āĻĒāĻ°ā§āĻā§
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of âŦ4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
āĻ¸ā§āĻĨāĻžāĻĒāĻŋāĻ¤ āĻšā§ā§āĻā§
ā§§ā§Ž āĻāĻžāĻ¨ā§, ā§§ā§¯ā§¨ā§Ž
āĻā§ā§āĻŦāĻ¸āĻžāĻāĻ
āĻāĻ°ā§āĻŽāĻāĻžāĻ°ā§
ā§¯,ā§¨ā§§ā§Ģ
